RS
Rob Slack
Chief Scientific OfficerDr. Rob Slack, PhD, FRSB, is Chief Scientific Officer of Vicore Pharma Holding AB (publ) from July 2026. He has experience in fibrosis and respiratory translational science and joined from GSK, where he served as Vice President and Head of Respiratory Biology. He was previously acting Chief Scientific Officer at Galecto. Over his career he has helped deliver multiple approved respiratory medicines, including vilanterol (Breo®, Trelegy®) and umeclidinium (Anoro®, Trelegy®) for asthma and COPD and led the discovery of the inhaled avß6 inhibitor GSK3008348 for IPF. A Fellow of the Royal Society of Biology with more than 60 publications, he holds a PhD from the University of Strathclyde.
Positions
- Company NameVicore Pharma Holding AB (publ)Stock CodeVCREPositionChief Scientific OfficerColleagues
- ASAhmed S. MousaChief Executive Officer
- HJHans J. G. C. P. SchikanIndependent Chairman
- HJHans JeppssonChief Financial Officer
- MNMikael NygårdChief Operating Officer
- HBHelen BarkerChief Technology Officer
- HHHeidi HunterIndependent Director
- JGJacob GunterbergIndependent Director
- EBElisabeth BjorkIndependent Director
- YBYasir B. Al-WakeelIndependent Director
